[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
April 2017

Injection-Site Cutaneous Pseudolymphoma Induced by a GM-CSF–Producing Tumor Cell Vaccine

Author Affiliations
  • 1Division of Dermatology, Department of Medicine, Washington University, St Louis, Missouri
  • 2Department of Pathology and Immunology, Washington University, St Louis, Missouri
  • 3Dermatopathololgy Center, Washington University, St Louis, Missouri
JAMA Dermatol. 2017;153(4):332-334. doi:10.1001/jamadermatol.2016.4988

We report 2 cases of cutaneous pseudolymphoma arising after injection of a granulocyte macrophage (GM)-colony stimulating factor (GM-CSF)–producing pancreatic tumor cell vaccine (GVAX).

A man in his 20s with metastatic pancreatic adenocarcinoma received an ipilimumab infusion and subcutaneous injections of GVAX as part of a phase 2 trial (NCT01896869). One week after the first GVAX injections, he developed intensely pruritic lesions surrounding the injection sites on the bilateral dorsal thighs and right upper arm. Examination revealed erythematous papulovesicles and concentric yellow-orange plaques surrounding injection sites (Figure 1A).

×